webinar recording available - register to watch

AI & multi-omics for translational research

Innovations driving drug discovery breakthroughs and shaping future-ready strategies

Overview

The future of translational research and the most exciting advances are happening at the intersection of AI, multi-omics, biomarker development, and biospecimen strategy, each essential for capturing the biological variability that shapes precision medicine. This panel brings together scientists, technologists, and strategists driving the next generation of biomarker & diagnostic discovery and validation. You’ll hear from leaders at Precision for Medicine, SOPHiA GENETICS, and Olink, part of Thermo Fisher; partners at the forefront of multi-omics integration, AI-powered analytics, genomics and high-plex proteomics as they discuss leading-edge practices and where the field is headed in 2026.

Key Discussion Topics:

Integrating Innovation: How SOPHiA GENETICS and Olink are pushing the boundaries of data interpretability, genomics, and proteomics for translational research.
Connecting Specimen to Signal: Precision for Medicine’s biospecimen experts will share how integrated sample collection and processing workflows ensure high-quality inputs for multi-omic assays and AI-driven analysis, enabling reproducible insights while accounting for biological diversity across diverse patient populations
AI-Driven Biomarker Development: How multi-omic data and machine learning are accelerating the connection between discovery biology and clinical endpoints through coordinated assay design
On the horizon for 2026: Explore how AI and multi-omics are shaping adaptive trial design, regulatory strategy, and the evolution of companion diagnostics.

Who Should Attend:

Built for biotech, pharma, and diagnostic researchers who are shaping the next generation of precision medicine:

Translational & biomarker discovery scientists
Computational biologists, AI/ML teams, and bioinformaticians
Clinical development & companion diagnostic leaders
R&D strategy and precision medicine program owners

watch now

watch the webinar

First name

Last name

Company

Job Title

Country

What phase of development are you most focused on for applying multi-omics and AI?

Preclinical

Phase I - II

Phase III

Post-market

Not sure yet

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Deb Phippard

Chief Scientific Officer, Precision for Medicine

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Philippe Menu

EVP, Chief Medical Officer & Chief Product Officer, SOPHiA GENETICS

Dr. Philippe Menu, MD, PhD, MBA, joined SOPHiA GENETICS in 2020 as Chief Medical Officer, bringing a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology, and business management consulting.

Before joining SOPHiA GENETICS, he spent 8 years at McKinsey & Company serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players, and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.

Philippe obtained his MD and PhD from the University of Lausanne and his MBA in life sciences from the Open University Business School.

Heng (Tony) Qian

Head of Data Science (North America), Olink, part of Thermo Fisher Scientific

Tony Qian leads the Americas Data Science team at Olink, driving innovation in proteomics research through continuous enhancements to the Olink data science ecosystem. His work focuses on empowering researchers with advanced analytical tools and scalable solutions. Previously, Tony specialized in developing infectious disease and genomics products within the in vitro diagnostics (IVD) industry, combining deep technical expertise with a strong understanding of clinical applications.

Rob Fannon

Head of Biospecimen Solutions, Precision for Medicine

Respected veteran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Master of Business Administration from Johns Hopkins University.

moderator

Surani Fernando

Healthcare journalist, writer & podcaster

Surani Fernando is a seasoned healthcare journalist and editor with over 13 years experience covering the biopharma industry. A Sydney native, she started her investigative journalism career in London covering clinical trials, M&A and financing deals for BioPharm Insight, later moving to New York to continue her work as an enterprise journalist and editorial leader for GlobalData and Reorg. She is now based in Madrid working as a freelance journalist, consultant writer and podcast producer. In November 2023, she launched the Raising Biotech podcast.